Skip to main content
main-content

Respiratory

Editor's pick

Triple combination CFTR modulator therapy shows potential for cystic fibrosis

pills

Combination therapy with a next-generation cystic fibrosis transmembrane conductance regulator corrector, together with tezacaftor and ivacaftor, may be a promising treatment option for cystic fibrosis, suggest findings from two studies published in The New England Journal of Medicine.

08-11-2018 | Respiratory | News | Article

Benefits of nintedanib extend to patients with advanced IPF

Results of a real-world study suggest that nintedanib delays lung function decline in patients with idiopathic pulmonary fibrosis irrespective of disease severity.

Source:

Respir Res 2018; 19: 203

01-11-2018 | Asthma | News | Article

COLUMBA results support long-term use of mepolizumab in patients with severe asthma

The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.

Source:

J Allergy Clin Immunol 2018; doi:10.1016/j.jaci.2018.09.033

18-10-2018 | Respiratory | News | Article

TWICS results suggest no role for low-dose theophylline as add-on therapy in COPD

The addition of low-dose theophylline to inhaled corticosteroids does not reduce the risk of exacerbations among patients with chronic obstructive pulmonary disease, findings from the TWICS trial indicate.

Source:

JAMA 2018; 320: 1541–1542, 1548–1559

11-10-2018 | Asthma | News | Article

Changing inhaler device does not compromise asthma treatment effectiveness

Results of a real-world study suggest that changing from a dry powder inhaler to a pressurized metered-dose inhaler is not associated with compromised treatment outcomes among patients with asthma.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.09.027

Twitter Icon Follow medwireNews

Click here
image credits